Uses and Limitations of Positron Emission Tomography in Clinical Pharmacokinetics/Dynamics (Part II)
- 1 April 1992
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 22 (4) , 274-283
- https://doi.org/10.2165/00003088-199222040-00003
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium AnalysisJournal of Cerebral Blood Flow & Metabolism, 1989
- F-18 deoxyglucose and stress N-13 ammonia positron emission tomography in anterior wall healed myocardial infarctionThe American Journal of Cardiology, 1988
- Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using11C-N-methyl-spiperoneActa Neurologica Scandinavica, 1987
- Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic TracersJournal of Neurochemistry, 1987
- Reversibility of Cardiac Wall-Motion Abnormalities Predicted by Positron TomographyNew England Journal of Medicine, 1986
- Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of LigandsJournal of Cerebral Blood Flow & Metabolism, 1986
- Strategies for in vivo Measurement of Receptor Binding Using Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1986
- Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and AffinityJournal of Cerebral Blood Flow & Metabolism, 1986
- Prediction of survival in glioma patients by means of positron emission tomographyJournal of Neurosurgery, 1985
- []-N-: The radioligand of choice for pett studies of the dopamine receptor in human brainLife Sciences, 1985